Evidence map›Paper›PMID 32002410›Full record

ArticleCase reports in nephrology and dialysis

A Case of Frequently Relapsing Minimal-Change Nephrotic Syndrome with Steroid-Induced Psychiatric Syndrome Treated by Low-Dose, Short-Term Steroid Therapy in Combination with Cyclosporine.

Isao Kondo, Yohei Arai, Akiyoshi Hamada, Kota Yamada, Shingo Shioji, Emi Sakamoto, Daisuke Katagiri, Manami Tada, Fumihiko Hinoshita

Open access · goldAbstract readCase Reports
In one paragraph

Article in Case reports in nephrology and dialysis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Isao KondoDepartment of Nephrology, National Center for Global Health and Medicine, Tokyo, Japan.
Yohei AraiDepartment of Nephrology, National Center for Global Health and Medicine, Tokyo, Japan.
Akiyoshi HamadaDepartment of Nephrology, National Center for Global Health and Medicine, Tokyo, Japan.
Kota YamadaDepartment of Nephrology, National Center for Global Health and Medicine, Tokyo, Japan.
Shingo ShiojiDepartment of Nephrology, National Center for Global Health and Medicine, Tokyo, Japan.
Emi SakamotoDepartment of Nephrology, National Center for Global Health and Medicine, Tokyo, Japan.
Daisuke KatagiriDepartment of Nephrology, National Center for Global Health and Medicine, Tokyo, Japan.
Manami TadaDepartment of Nephrology, National Center for Global Health and Medicine, Tokyo, Japan.
Fumihiko HinoshitaDepartment of Nephrology, National Center for Global Health and Medicine, Tokyo, Japan.
National Center for Global Health and Medicine · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adults with minimal-change nephrotic syndrome (MCNS) generally receive oral prednisolone (PSL) at an initial dosage of 1.0 mg/kg/day for a minimum of 4 weeks, with 80% of patients achieving clinical remission. However, relapses are frequent, necessitating repeated treatment with high-dose PSL. Long-term treatment with high-dose steroids increases the risk of steroid toxicities, such as diabetes mellitus, gastric complications, infections, osteoporosis, and steroid-induced psychiatric syndrome (SIPS), which may compromise the patient's quality of life. Strategies are therefore needed to reduce the dosage and duration of steroid therapy for frequently relapsing MCNS (FRNS). Here, we suggest a new combination therapy of low-dose and short-term steroid with cyclosporine (CsA). We encountered an adult patient who developed recurrence of FRNS with depression arising from SIPS and was treated using low-dose, short-term PSL combined with CsA. He was successfully treated with PSL at an initial dosage of 0.3 mg/kg/day (20 mg/day) for just 2 weeks combined with CsA, allowing earlier induction of complete remission. We then promptly reduced the dose of PSL to below a physiological dosage (5 mg/day) over 3 weeks without relapse after episodes of SIPS and quickly resolved psychiatric symptoms. CsA in combination with PSL can reduce the initial dosage of PSL, shorten the time to remission, and easily maintain clinical remission. This protocol appears clinically useful and potentially applicable as a future treatment strategy for FRNS troubled by SIPS.

Indexed as

CyclosporineDepressionMinimal-change nephrotic syndromePrednisoloneSteroid-induced psychiatric syndrome

Identifiers

PMID32002410
PMCPMC6984147
OpenAlexW2999854091

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.